Investor Relations

Corporate Profile

Corporate Profile

Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine.  sd-rxRNA therapeutics can be used as a standalone treatment or in combination with other modalities.  Our development strategy is to tackle different immune escape mechanisms to treat solid tumors in three main areas:

  • Boosting immune cell function
  • Boosting immune effector cell fitness and persistence, and
  • Increasing tumor cell recognition and immunotherapy susceptibility

Essentially, we aim to maximize the power of our sd-rxRNA therapeutic compounds by weaponizing therapeutic immune effector cells to attack cancer and ultimately provide patients battling terminal cancers with a powerful new treatment option that goes beyond current treatment modalities.